Advanced RSV Vaccine in Dubai

The RSV vaccine (AREXVY) is the first approved vaccine against respiratory syncytial virus, designed specifically for adults aged 60 and older. RSV is a common respiratory virus that causes mild cold-like symptoms in healthy younger adults but can cause severe lower respiratory tract infections, including bronchiolitis and pneumonia, in elderly and immunocompromised individuals. AREXVY is a single-dose vaccine that reduces the risk of RSV-associated lower respiratory tract disease by approximately 83%.

AREXVY is administered as a single intramuscular injection. Unlike many other vaccines, no booster doses are currently recommended. Clinical trial data shows that a single dose of AREXVY provides significant protection across at least two consecutive RSV seasons. As more long-term data becomes available, recommendations regarding the need for future booster doses may be updated by health authorities.

The ideal time to receive the RSV vaccine in Dubai is September or October, before the peak RSV season which typically runs from November through March in the UAE. Vaccination before the season begins allows two to four weeks for the immune system to develop optimal antibody levels. However, the vaccine can be administered at any time of year for individuals who missed the pre-season window, as RSV circulates year-round at lower levels and protection extends across multiple seasons.

Yes, AREXVY was specifically studied in adults aged 60 and older, including those with stable chronic conditions such as COPD, asthma, heart failure, and diabetes. The clinical trials enrolled over 25,000 participants aged 60 and above and demonstrated a favorable safety profile across all subgroups. Common side effects include injection site pain, fatigue, muscle pain, and headache, typically lasting one to two days. Our physicians assess each patient's individual health status to confirm suitability before vaccination.

DCDC is committed to offering evidence-based preventive medicine as soon as new vaccines and treatments become available. AREXVY represents the culmination of over 60 years of RSV vaccine research and addresses a significant unmet medical need for older adults. By stocking AREXVY early, we ensure that our elderly patients and those with chronic respiratory or cardiac conditions can access this important protection without waiting for broader rollout across the UAE healthcare system.

Current clinical guidance supports administering the RSV vaccine and the influenza vaccine at the same visit, given in different arms. Both vaccines target respiratory illnesses that peak during the winter months in the UAE, making co-administration a convenient option for elderly patients. Our clinical team will advise on the best approach based on your vaccination history and health status, ensuring that each vaccine is administered safely and effectively.

The most common side effects of AREXVY are injection site pain (reported by approximately 61% of recipients), fatigue (34%), muscle pain (29%), and headache (27%). These side effects are generally mild to moderate and resolve within one to two days. Less common side effects include joint pain and fever. Serious adverse events were rare in clinical trials and occurred at similar rates in the vaccine and placebo groups. All patients are observed for 15 minutes after vaccination as a standard safety precaution.

No, the RSV vaccine specifically targets respiratory syncytial virus only. It does not provide protection against SARS-CoV-2 (COVID-19), influenza, or other respiratory viruses. For comprehensive respiratory protection during the winter season, we recommend that elderly patients receive the RSV vaccine, the annual influenza vaccine, and any recommended COVID-19 boosters. These vaccines can be administered during the same visit or at separate appointments based on patient preference and clinical guidance.